Eli Lilly Rises 1.56% on 3.44 Quant Score; Seeks Foundayo Approval in 40 Countries
LLY•Eli Lilly gained 1.56% as the Health Care Select Sector SPDR Fund rose 3%, while its Quant rating ranks 3.44 among S&P Health Care stocks. Only 1%-2% of patients use Lilly’s obesity drugs; the company seeks approval for oral pill Foundayo in 40 countries while expanding Zepbound internationally.
1. Healthcare Sector Rally Spurs Eli Lilly Stock
Eli Lilly’s shares rose 1.56% as the Health Care Select Sector SPDR Fund advanced 3%, driven by investor rotation into defensive names. Its Quant rating ranks 3.44 among S&P Health Care stocks, demonstrating market resilience as technology valuations adjust.
2. Global Obesity Drug Expansion Strategy
Lilly reports that only 1%-2% of patients currently use its obesity therapies. The company is pursuing approval for its oral pill Foundayo in 40 countries and expanding distribution of Zepbound internationally to capture unmet global demand.
